Candel Therapeutics, Inc. (CADL), a clinical stage biopharmaceutical company, announced Thursday positive interim survival data from the ongoing randomized phase 2 clinical trial of CAN-2409 in Non-Metastatic Pancreatic Cancer.
Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in.
NEEDHAM, Mass., Dec. 12, 2023 Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer,.
Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma after experimental treatment with CAN-2409 Estimated overall.
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.